BMS 903452

Drug Profile

BMS 903452

Alternative Names: BMS-903452

Latest Information Update: 02 May 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antihyperglycaemics
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 02 May 2016 Chemical structure information added
  • 26 Apr 2016 No recent reports on development identified - Phase-I for Type-2 diabetes mellitus in USA (PO, liquid & suspension)
  • 14 Mar 2012 Bristol-Myers Squibb completes its phase I trial for Type-2 diabetes mellitus in USA (NCT01240980)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top